<?xml version='1.0' encoding='utf-8'?>
<document id="26825640"><sentence text="Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects."><entity charOffset="10-21" id="DDI-PubMed.26825640.s1.e0" text="Ondansetron" /><entity charOffset="25-34" id="DDI-PubMed.26825640.s1.e1" text="Metformin" /><pair ddi="false" e1="DDI-PubMed.26825640.s1.e0" e2="DDI-PubMed.26825640.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26825640.s1.e0" e2="DDI-PubMed.26825640.s1.e1" /></sentence><sentence text="The 5-hydroxytryptamine-3 (5-HT3) receptor antagonists such as ondansetron have been used to prevent and treat nausea and vomiting for over 2 decades"><entity charOffset="4-25" id="DDI-PubMed.26825640.s2.e0" text="5-hydroxytryptamine-3" /><entity charOffset="63-74" id="DDI-PubMed.26825640.s2.e1" text="ondansetron" /><pair ddi="false" e1="DDI-PubMed.26825640.s2.e0" e2="DDI-PubMed.26825640.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26825640.s2.e0" e2="DDI-PubMed.26825640.s2.e1" /></sentence><sentence text=" This study was to determine whether ondansetron could serve as a perpetrator drug causing transporter-mediated drug-drug interactions in humans"><entity charOffset="37-48" id="DDI-PubMed.26825640.s3.e0" text="ondansetron" /></sentence><sentence text=" Twelve unrelated male healthy Chinese volunteers were enrolled into a prospective, randomized, double-blind, crossover study to investigate the effects of ondansetron or placebo on the pharmacokinetics of and the response to metformin, a well-characterized substrate of organic cation transporters and multidrug and toxin extrusions (MATEs)"><entity charOffset="156-167" id="DDI-PubMed.26825640.s4.e0" text="ondansetron" /><entity charOffset="226-235" id="DDI-PubMed.26825640.s4.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26825640.s4.e0" e2="DDI-PubMed.26825640.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26825640.s4.e0" e2="DDI-PubMed.26825640.s4.e1" /></sentence><sentence text=" Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo (18"><entity charOffset="1-12" id="DDI-PubMed.26825640.s5.e0" text="Ondansetron" /><entity charOffset="75-84" id="DDI-PubMed.26825640.s5.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.26825640.s5.e0" e2="DDI-PubMed.26825640.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26825640.s5.e0" e2="DDI-PubMed.26825640.s5.e1" /></sentence><sentence text="3 ± 5" /><sentence text="05 versus 15" /><sentence text="2 ± 3" /><sentence text="23; P = 0" /><sentence text="006) and apparently decreased the renal clearance of metformin by 37% as compared with placebo (P = 0"><entity charOffset="53-62" id="DDI-PubMed.26825640.s10.e0" text="metformin" /></sentence><sentence text="001)" /><sentence text=" Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10"><entity charOffset="16-27" id="DDI-PubMed.26825640.s12.e0" text="ondansetron" /><entity charOffset="80-87" id="DDI-PubMed.26825640.s12.e1" text="glucose" /><entity charOffset="139-146" id="DDI-PubMed.26825640.s12.e2" text="glucose" /><entity charOffset="180-187" id="DDI-PubMed.26825640.s12.e3" text="glucose" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e0" e2="DDI-PubMed.26825640.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e0" e2="DDI-PubMed.26825640.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e0" e2="DDI-PubMed.26825640.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e0" e2="DDI-PubMed.26825640.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e1" e2="DDI-PubMed.26825640.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e1" e2="DDI-PubMed.26825640.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e1" e2="DDI-PubMed.26825640.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e2" e2="DDI-PubMed.26825640.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26825640.s12.e2" e2="DDI-PubMed.26825640.s12.e3" /></sentence><sentence text="4 ± 1" /><sentence text="43) as compared with placebo (11" /><sentence text="5 ± 2" /><sentence text="29 mmol∙mg/l) (P = 0" /><sentence text="020)" /><sentence text=" It remains possible that ondansetron itself may affect glucose homeostasis in human subjects, but our clinical study, coupled with our previous findings in cells and in animal models, indicates that ondansetron can cause a drug-drug interaction via its potent inhibition of MATE transporters in humans"><entity charOffset="26-37" id="DDI-PubMed.26825640.s18.e0" text="ondansetron" /><entity charOffset="56-63" id="DDI-PubMed.26825640.s18.e1" text="glucose" /><entity charOffset="200-211" id="DDI-PubMed.26825640.s18.e2" text="ondansetron" /><pair ddi="false" e1="DDI-PubMed.26825640.s18.e0" e2="DDI-PubMed.26825640.s18.e0" /><pair ddi="false" e1="DDI-PubMed.26825640.s18.e0" e2="DDI-PubMed.26825640.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26825640.s18.e0" e2="DDI-PubMed.26825640.s18.e2" /><pair ddi="false" e1="DDI-PubMed.26825640.s18.e1" e2="DDI-PubMed.26825640.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26825640.s18.e1" e2="DDI-PubMed.26825640.s18.e2" /></sentence><sentence text=" " /></document>